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Abstract
Background—Continuous antiretroviral therapy (ART) is important for maintaining viral 
suppression. This analysis estimates prevalence of and reason for ART discontinuation.
Methods—Three-stage sampling was used to obtain a nationally representative, cross-sectional 
sample of HIV-infected adults receiving HIV care. Face-to-face interviews and medical record 
abstractions were collected from June 2009 to May 2010. Data were weighted based on known 
probabilities of selection and adjusted for nonresponse. Patient characteristics of ART 
discontinuation, defined as not currently taking ART, stratified by provider-initiated versus non–
provider-initiated discontinuation, were examined. Weighted logistic regression models predicted 
factors associated with ART discontinuation.
Results—Of adults receiving HIV care in the United States who reported ever initiating ART, 
5.6% discontinued treatment. Half of those who discontinued treatment reported provider-initiated 
discontinuation. Provider-initiated ART discontinuation patients were more likely to have a nadir 
CD4 ≥200 cells per cubic millimeter. Non–provider-initiated ART discontinuation patients were 
more likely to have unmet need for supportive services and to have not received HIV care in the 
past 3 months. Among all patients who discontinued, younger age, female gender, not having 
continuous health insurance, incarceration, injection drug use, nadir CD4 count ≥200 cells per 
cubic millimeter, unmet need for supportive services, no care in the past 3 months and HIV 
diagnosis ≥5 years before interview were independently associated with ART discontinuation.
Conclusions—These findings inform development of interventions to increase ART persistence 
by identifying groups at increased risk of ART discontinuation. Evidence-based interventions 
targeting vulnerable populations are needed and are increasingly important as recent HIV 
treatment guidelines have recommended universal ART.
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Combination antiretroviral therapy (ART) provides a range of benefits to HIV-infected 
patients such as increased survival, improved immune status and decreased morbidity, and 
opportunistic infections.1–5 Through viral suppression, ART reduces the likelihood of sexual 
transmission of HIV to uninfected partners.6–9 Recognition of these benefits has led to 
recent treatment guideline changes to recommend ART for all HIV-infected patients 
regardless of immune status.10 A major challenge of ART is that treatment must be 
continuous to receive benefits and in most cases requires a lifelong commitment.10 Many 
factors can affect a patient’s ability to sustain treatment and may lead to ART 
discontinuation.
Treatment interruptions can be planned or unplanned, short or long term, or permanent. The 
decision to discontinue ART can be made by the patient or by the provider. Some reasons 
providers may recommend discontinuing treatment include severe drug toxicity, intervening 
illness, surgery that precludes oral therapy, or unavailability of antiretroviral medication.11 
Patients may also choose to discontinue treatment due to factors such as personal beliefs 
(patient feels healthy and does not see the need to be on ART any longer), structural barriers 
(incarceration or transportation difficulties), or financial limitations or insurance status (loss 
of employment or insurance).
Although some therapy interruptions are clinically indicated, the negative effects of therapy 
discontinuation are well documented, with studies reporting that premature ART 
discontinuation results in decreased survival, lower CD4 count, increased viremia, and 
increased drug resistance.12–16 Moreover, sexual transmission of HIV has been documented 
in patients who discontinued ART regimens.17
Previous research on ART utilization has focused primarily on adherence.18–21 
Examinations of the prevalence and predictors of ART discontinuation have demonstrated 
that certain patients are more likely to discontinue ART. Substance use,22 injection drug 
use,23 disease severity,14,22,24,25 younger age,14,25,26 racial/ethnic minorities,26,27 female 
gender,22,28 unemployment,28 perceived HIV stigma,29 fear of discrimination,30 mental 
health,14,24,28,31,32 and side effects33 have been associated with ART discontinuation. 
However, these studies lack generalizability since they were conducted on subpopulations of 
HIV-infected patients, such as patients from 1 or a small group of clinics or hospitals, 
women only, or patients with a history of substance abuse. There are no population-based 
estimates of ART discontinuation nor has the distinction between provider-initiated and 
non–provider-initiated ART discontinuation been examined in previous literature. ART 
discontinuation and its effects will become an increasingly important issue as patients and 
providers come to adopt current universal treatment guidelines and the treatment eligible 
population increases. This analysis aims to estimate the weighted prevalence of ART 
initiation, current ART use and discontinuation, and to describe the main reason for 
discontinuation among a representative sample of HIV-infected adults receiving HIV care in 
the United States. In addition, we examined differences in the characteristics of patients who 
discontinued ART per provider recommendation versus those who self-initiated 
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discontinuation or discontinued due to structural barriers. Finally, we investigated predictors 
of ART discontinuation. These findings can inform the development and evaluation of 
interventions to increase ART persistence among populations who are at increased risk of 
self-initiated ART discontinuation.
METHODS
The Medical Monitoring Project (MMP) is a supplemental HIV surveillance system that 
uses a 3-stage sampling design to obtain nationally representative, annual, cross-sectional 
samples of HIV-infected adults receiving medical care for HIV in the United States to 
monitor clinical and behavioral outcomes.33–35 States and territories are sampled first, then 
outpatient facilities providing HIV care in these areas, and finally adults aged 18 years or 
older receiving at least 1 medical care visit in the sampled facilities between January and 
April each year are selected. For this analysis, we used data from the 2009 MMP data 
collection cycle, which were collected through face-to-face interviews with sampled patients 
and a linked medical record abstraction between June 2009 and May 2010. Factors 
associated with facility and patient nonresponse were determined by conducting a 
nonresponse bias analysis using data collected on sampled facilities and patients. Data were 
weighted on the basis of known probabilities of selection at state or territory, facility, and 
patient levels. At the patient level, data were weighted to adjust for nonresponse by using 
predictors of patient-level response, including facility size, race/ethnicity, time since HIV 
diagnosis, and age group. The Center for Disease Control and Prevention’s National Center 
for HIV, Viral Hepatitis, STD and TB Prevention has determined that MMP is a public 
health surveillance activity used for disease control program or policy purposes.36 Because 
National Center for HIV, Viral Hepatitis, STD and TB Prevention determined that MMP is 
not research, it is not subject to human subjects regulations including federal investigational 
review board.37 However, several participating states, territories, and facilities obtained local 
Investigational Review Board approval to conduct MMP.
Measures
Outcome Variable—ART use was ascertained by self-report. Patients were asked if they 
had ever taken antiretroviral medicines for their HIV. Patients who answered “yes” were 
classified as ever initiating ART. Additionally, patients were asked if they were currently 
taking any antiretroviral medicines for HIV at the time of the interview; if they answered 
“yes” they were defined as current ART-users. ART discontinuation was defined as patients 
who reported ever initiating ART but were not currently taking ART. Participants were also 
asked “What is the main reason you aren’t currently taking any antiretroviral medicines?” 
Self-reported main reason for ART discontinuation was grouped into the following 
categories: (1) physician-advised treatment discontinuation, (2) individual/personal reasons, 
(3) therapy-related reasons, and (4) structural barriers to continuation. Examples of 
individual/personal reasons included felt healthy or CD4 and viral load values were good, 
depressed or overwhelmed, did not want to think about being HIV-positive, drinking or 
using drugs, or self-perceived therapy-related reasons such as worried about long-term 
effects of medication. Therapy-related examples included side effects of ART, difficulty 
swallowing pills, or allergic reactions to medications. Structural barriers included 
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incarceration, money or insurance issues, and difficulty obtaining an appointment at or 
transportation to a doctor’s office. We created a separate variable that distinguished who 
initiated ART discontinuation by grouping patients into the following categories: provider-
initiated ART discontinuation and non–provider-initiated ART discontinuation. Provider-
initiated ART discontinuation included all patients who reported that they discontinued 
because their physician advised treatment discontinuation. Non–provider-initiated ART 
discontinuation included patients who discontinued for individual/personal reasons, self-
perceived therapy-related reasons, and structural barriers.
Covariates—Sociodemographic variables (age, gender, sexual orientation, race/ethnicity, 
income, and education) were self-reported during the interview. Patients reported health 
insurance coverage, incarceration, homelessness, time since HIV diagnosis and alcohol and 
substance use during the previous 12 months. An 8-item Patient Health Questionnaire 
depression scale (PHQ-8) diagnostic algorithm was used to ascertain any major or other 
depression.38 A dichotomous variable for unmet need for supportive services was created 
and defined as needing but not receiving any of the following services: adherence support, 
food/meals, AIDS Drug Assistance Program, public benefits such as Supplemental Security 
Income or Social Security Disability Insurance, transportation, mental health care, substance 
abuse, and/or HIV case management. No receipt of care in the past 3 months was calculated 
from self-reported month and year of most recent HIV medical appointment at any care 
facility. A binary outcome of inadequate health literacy based on self-report was defined as 
needing help reading hospital forms always, most of the time, about half the time or rarely 
versus never needing help.39 Most recent viral load value, nadir CD4, and geometric mean 
CD4 count (the mean of all CD4 counts recorded during the past 12 months) were 
determined from data in the medical record. Viral suppression was defined as having HIV-1 
RNA that was undetectable or <400 copies per milliliter at the most recent measurement in 
the past 12 months.
Data Analysis
Weighted univariate frequencies were calculated to estimate the prevalence and 95% 
confidence intervals for ART use among US patients receiving HIV care during January 
through April 2009. Weighted modified Rao–Scott χ2 examined differences in 
sociodemographics, behavioral and clinical characteristics among patients who discontinued 
ART versus current ART-users. Weighted univariate frequencies described main reason for 
ART discontinuation. We calculated weighted modified Rao–Scott χ2 to compare patient 
characteristics of provider-initiated and non–provider-initiated ART discontinuation. Finally, 
we performed weighted bivariate and multivariable logistic regression analyses to identify 
factors associated with all ART discontinuation and built separate models stratified by 
provider-initiated and non–provider-initiated ART discontinuation. Given limited literature 
on predictors of ART discontinuation, we applied an empirical approach to our model 
selection strategy. Weighted multivariable models were built according to a backward 
elimination strategy that initially included all variables associated with ART discontinuation 
at P ≤ 0.10 and retained variables that remained significant at P ≤ 0.05. All analyses 
accounted for the complex sampling design and selection probabilities and were conducted 
using SAS version 9.2 (SAS Institute, Cary, NC).
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All sampled states and territories participated in MMP [California (including the separately 
funded jurisdictions of Los Angeles County and San Francisco), Delaware, Florida, Georgia, 
Illinois (including Chicago), Indiana, Michigan, Mississippi, New Jersey, New York 
(including New York City), North Carolina, Oregon, Pennsylvania (including Philadelphia), 
Puerto Rico, Texas (including Houston), Virginia, and Washington]. Within these areas, 603 
HIV care facilities were sampled and of these, 461 participated in MMP (facility response 
rate = 76%). Of the 9338 persons sampled from the participating facilities, 4217 completed 
both an interview and a linked medical record abstraction (adjusted patient-level response 
rate = 51%) for a combined response rate of 39%. After weighting for probability of 
selection and nonresponse, these 4217 participants were estimated to represent a population 
of 421,186 HIV-infected adults receiving medical care in the United States between January 
and April 2009.
Antiretroviral Therapy Use
An estimated 93% of adults receiving HIV care in the United States ever initiated ART. The 
majority of these ART initiators were currently taking ART (94%) and 6% or an estimated 
21,769 persons discontinued ART (Table 1).
Sociodemographic Characteristics Associated With ART Discontinuation
Overall, the majority of the population was male, self-identified as heterosexual or straight, 
had some college education or more, had an income above the poverty level and had 
insurance for the entire previous 12 months (Table 2).
There were significant sociodemographic differences between the population reporting ART 
discontinuation compared with those reporting current ART use. Compared with current 
ART-users, those who discontinued ART were younger, more likely to be female and less 
likely to identify as homosexual. More African Americans and mixed or other race/
ethnicities discontinued ART. Those who discontinued ART were less likely to have 
insurance for the entire previous 12 months and were more likely to have been incarcerated 
and homeless in the previous 12 months.
Behavioral, Clinical, and Other Characteristics Associated With ART Discontinuation
Compared with the population of current ART-users, those who discontinued were 
significantly more likely to use injection drugs, non–injection drugs and stimulants in the 
past 12 months (Table 3). ART discontinuation patients were more likely to have major or 
other depression in the past 12 months compared with current ART-users. ART 
discontinuation patients were significantly more likely to have a higher nadir CD4 count 
(≥200 cells/mm3) and a detectable viral load than current ART-users. Finally, ART 
discontinuation patients were more likely to have an unmet need for supportive services in 
the past 12 months and to have not received care in the last 3 months.
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Main Reason for ART Discontinuation
The most common reported reason for ART discontinuation was a doctor’s advice to delay 
or stop treatment (51%). Other reasons for discontinuation included individual/personal 
reasons (16%), therapy-related concerns (20%), structural barriers (12%), or another or 
unknown reason (2%).
Comparison of Provider-Initiated Versus Non–Provider-Initiated ART Discontinuation
Given that half of the ART discontinuation population discontinued on the recommendation 
of their doctor, we stratified ART discontinuation patients into 2 subpopulations based on 
who initiated ART discontinuation to examine differences in sociodemographic and other 
characteristics (Table 4). Patients who discontinued ART due to provider recommendation 
were significantly more likely to have a nadir CD4 ≥200 cells per cubic millimeter compared 
with those who initiated discontinuation themselves or discontinued due to structural 
barriers. Non–provider-initiated ART discontinuation patients were significantly more likely 
to have unmet needs for supportive services and to have not received care in the past 3 
months. No other significant differences between provider-initiated and non–provider-
initiated ART discontinuation patients were found.
Predictors of ART Discontinuation
Among all patients who discontinued, younger age, female gender, not having continuous 
health insurance, incarceration, injection drug use, nadir CD4 count ≥200 cells per cubic 
millimeter, unmet need for supportive services, no receipt of care in the past 3 months, and 
HIV diagnosis ≥5 years before interview were independently associated with ART 
discontinuation (Table 5). For patients who discontinued ART due to provider 
recommendation, younger age, female gender, heterosexual and bisexual self-identified 
sexual orientation (compared with homosexual), stimulant use, nadir CD4 count ≥200 cells 
per cubic millimeter, and HIV diagnosis ≥10 years before interview were associated with 
higher odds of discontinuing ART. Among patients who had non–provider-initiated ART 
discontinuation, female gender, not having continuous health insurance over the past 12 
months, injection drug use, non–injection drug use, unmet need for supportive services in 
the past 12 months, and patients who did not receive care in the past 3 months had greater 
odds of discontinuing ART.
DISCUSSION
Approximately 1 of every 20 adults receiving HIV care in the United States who initiated 
ART discontinued treatment. We believe this is the first representative estimate of ART 
discontinuation among adults receiving HIV care in the United States.
Aside from some clinically necessary interruptions, successful HIV management requires 
lifelong ART adherence once treatment is initiated.10 Among our study population, half of 
the patients who discontinued ART did so based on their provider’s recommendation and the 
other half discontinued at their own initiative or due to a structural barrier. We, therefore, 
explored potential population differences between non–provider-initiated and provider-
initiated ART discontinuation and found that patients with nadir CD4 ≥200 cells per cubic 
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millimeter had higher odds of provider-initiated ART discontinuation. This finding likely 
reflects the treatment recommendations in place between June 2009 and May 2010 when 
these data were collected. In 2009, treatment guidelines strongly recommended ART for 
patients with a CD4 count <350 cells per cubic millimeter and recommended ART for 
patients with a CD4 count between 350 and 500 cells per cubic millimeter.40 Therefore, the 
patients in our analysis who discontinued ART on their provider’s recommendation may 
have been advised to do so because a previously low CD4 count improved or if they 
presented to a health care provider for the first time with a CD4 count ≥350 cells per cubic 
millimeter. We found no evidence that providers were recommending ART discontinuation 
based on patient characteristics such as homelessness or injection drug use.41,42
Similar to previous studies, we found that younger patients were more likely to discontinue 
ART.14,25,26 Young age was also significant for provider-initiated ART discontinuation. 
Younger HIV-positive patients have also been shown to have lower ART adherence (which 
may be understood as a brief ART discontinuation) compared with older patients possibly 
because of more frequent substance use, lack of experience managing illnesses, lack of 
perceived treatment benefits, lower self-efficacy, and lack of perceived threat of illness.43,44 
We also found that women were more likely to discontinue ART in all 3 models, consistent 
with other studies on ART persistence.22,28 More frequent HIV medication side effects and 
toxicity reported by women compared with men45,46 may account for the lower ART 
persistence observed in women. We found that injection drug use in the past 12 months was 
associated with significantly increased odds of discontinuing ART, which is consistent with 
other studies.47–49 This was true among all patients and among non–provider-initiated 
discontinuation. Additionally, incarceration in the past 12 months was also associated with 
ART discontinuation.48,49
We observed that higher immune status, as indicated by nadir CD4 ≥200 cells per cubic 
millimeter, was associated with overall ART discontinuation and provider-initiated ART 
discontinuation, which to the best of our knowledge has not been described in previous 
studies. Although not a significant predictor in our final model of non–provider-initiated 
ART discontinuation, some patients with a high nadir CD4 self-initiated ART 
discontinuation (n = 60; Table 4). One possible explanation for this finding may be that 
healthier individuals may not feel there are benefits to their health by continuing with ART. 
Gao et al50 found that severely ill HIV-positive patients were more likely to perceive a 
higher risk of complications if they did not adhere to treatment compared with asymptomatic 
HIV-positive patients and found that those with higher immune status were significantly less 
adherent to their ART regimen than patients with poorer immune status.
Unmet need for any supportive service was also associated with nonprovider ART 
discontinuation, which is not unexpected, given that many supportive services aim to help 
HIV-positive individuals effectively manage their disease and adhere to care visits and 
treatment. Although there is no previous research showing an effect of supportive services 
on consistent ART use, Kushel et al51 found that case management improved ART 
adherence and severely food-insecure patients have been found to have significantly poorer 
ART adherence and viral suppression.52,53 Receipt of 6 or more mental health care visits in 
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the past year among patients with a psychiatric diagnosis has also been associated with 
increased ART persistence.32
Unlike several previous studies,26,27 we did not find independent racial/ethnic disparities in 
ART discontinuation. African Americans in our analysis were disproportionately younger, 
female and incarcerated, factors significant in our overall multivariate model. We also did 
not find an independent association between depression and ART discontinuation contrary to 
what has been previously reported.14,24,28,31,54 HIV-positive women are more likely to be 
depressed than HIV-positive men,55 which may explain why depression is no longer 
associated with ART discontinuation when we controlled for gender in our final model. 
Additionally, depression has been shown to decrease HIV care retention56; patients 
experiencing depression and who are not in care are less likely to be captured by MMP. 
Finally, our depression measure only captures patients who are currently experiencing 
depressive symptoms and not treatment of depression, so patients who are currently being 
treated for depression may not be captured by this measure.
This analysis is subject to several limitations. ART discontinuation was self-reported and 
information regarding how long the patient was taking ART before discontinuing and when 
the discontinuation occurred was not recorded in the interview. This could not be verified 
from medical records because only the prescription for ART is documented in the medical 
record, not if the medication was actually taken by the patient. Specific regimens of ART 
were not evaluated in our analysis and ART adherence could be affected by the tolerability, 
pill burden, and other factors such as the convenience of administration of the ART regimen 
taken.23 Our measure of ART discontinuation covers current ART use; those who are 
classified as current ART-users could have had periods of ART discontinuation in the past 
that we could not measure. Additionally, MMP samples people receiving HIV care in the 
United States and does not include people who discontinue ART after dropping out of care. 
As a result, our estimate likely underestimates the proportion of ART discontinuation in the 
entire population of people living with HIV. Similarly, limiting the data collection to people 
receiving HIV care in the United States has implications for generalizability to the entire 
population of HIV-infected individuals including those who have dropped out of care or 
have never been in care. Furthermore, because this is a cross-sectional observational 
analysis, we were able to assess associations with ART discontinuation but causality and 
temporality cannot be determined.
Many of the measures used in this analysis were self-reported and subject to recall and 
social-desirability bias. If patients were less likely to report stigmatized information such as 
ART discontinuation, incarceration, and injection drug use, such underreporting could result 
in an underestimation of the association between ART discontinuation and injection drug 
use and incarceration. However, interviewers were trained by CDC staff to conduct the 
interview in an impartial manner to minimize social-desirability bias and used standardized 
response cards (calendars, pictures of HIV medications, and others) to assist in patient 
recall. Although ART discontinuation was self-reported, we evaluated the validity of self-
report by looking at most recent viral load from the medical record, and the majority (83%) 
of patients who reported discontinuation had a detectable viral load according to their most 
recent test result.
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Despite these limitations, the probability sampling design and the fact that data were 
weighted to represent the entire population of adults receiving HIV care in the United States 
from January to April 2009 are major strengths of this study. As such, this analysis provides 
valuable information about factors associated with ART discontinuation and reasons for 
discontinuation. Looking at ART discontinuation in a care context where there is the 
potential to intervene and ensure ART adherence is valuable, particularly as the most recent 
treatment guidelines now recommend universal HIV treatment regardless of immune 
status.10 Efforts to understand patterns of treatment discontinuation, personal health beliefs 
(not measured in this analysis), and behaviors that could affect persistence will become 
increasingly important to evaluate which populations are at risk of not maintaining lifelong 
treatment. Developing and evaluating targeted interventions and providing supportive 
services toward populations vulnerable to ART discontinuation are needed because such 
interventions and support might reduce disparities in HIV treatment, which will ultimately 
contribute to a reduction in HIV transmission and improvements in the health of HIV-
infected patients.
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93.3 92.2 to 94.3




94.4 93.7 to 95.2
  ART





5.6 4.8 to 6.3
CI, confidence interval.
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